This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignees: National Institute of Health and Medical Research, Université Paris-Saclay, Université Paris—sud. Active years: 2020-2026.
Company Filing History:
3 out of 1,853 
2 out of 98 
1 out of 100 
Years Active: 2020-2026
Title: Gabriel Ayme: Innovator in Hemostasis Research
Introduction
Gabriel Ayme, based in Le Kremlin Bicetre, France, is a distinguished inventor known for his innovative contributions to the field of hemostasis. With two registered patents under his name, he is making significant strides in medical science, particularly regarding blood coagulation and therapeutic applications.
Latest Patents
Ayme's most recent inventions focus on anti-VWF D'D3 single-domain antibodies. His patents detail the development of isolated single-domain antibodies directed against the von Willebrand Factor (VWF) D'D3 domain. These antibodies are integrated into chimeric polypeptides, specifically blood clotting factors, aimed at therapeutic use in preventing and treating hemostatic disorders. Additionally, his inventions propose innovative methods to extend or increase the half-life of therapeutic polypeptides by incorporating at least one sdAb directed against the VWF D'D3 domain.
Career Highlights
During his career, Gabriel Ayme has been associated with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paris-Saclay. His work in these establishments underscores his commitment to advancing therapeutic options in the medical field, particularly in understanding blood coagulation mechanisms and their clinical implications.
Collaborations
Throughout his career, Ayme has had significant collaborations with notable colleagues, including Petrus Lenting and Céline Denis. These partnerships have fostered a productive exchange of ideas, leading to groundbreaking research and innovations in their chosen field.
Conclusion
Gabriel Ayme stands out as an influential figure in the realm of biomedicine, particularly within the context of hemoglobin and blood clotting advancements. His innovative patents and collaborative efforts continue to pave the way for future research and developments that promise to enhance therapeutic applications in treating hemostatic disorders. As he moves forward, his contributions will undoubtedly leave a lasting impact on the medical landscape.